Komal Jhaveri
科马尔·贾韦里
MD, FACP
Attending Physician, Breast Medicine Service乳腺医学部主治医师
👥Biography 个人简介
Komal Jhaveri is a prominent investigator in hormone receptor-positive breast cancer at MSKCC, with expertise in CDK4/6 inhibitors, PI3K/AKT pathway inhibitors, and endocrine resistance mechanisms. Her work shapes next-generation treatments for ER+ metastatic breast cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
CDK4/6 Inhibitor Combinations and Resistance
Investigated mechanisms of CDK4/6 inhibitor resistance and novel combination strategies, informing treatment sequencing in ER+ metastatic breast cancer.
PI3K/AKT Pathway Targeting in Breast Cancer
Led early-phase trials of PI3K inhibitors including alpelisib and novel AKT inhibitors, advancing precision therapy for PIK3CA-mutated ER+ breast cancer.
Representative Works 代表性著作
Alpelisib plus fulvestrant in PIK3CA-mutated HR+/HER2- breast cancer (SOLAR-1)
New England Journal of Medicine (2019)
Established alpelisib as standard therapy for PIK3CA-mutated ER+ metastatic breast cancer, enabling biomarker-driven treatment.
Novel CDK4/6 inhibitor combinations in endocrine-resistant metastatic breast cancer
Journal of Clinical Oncology (2022)
Demonstrated activity of next-generation CDK4/6 combinations in patients who progressed on prior CDK4/6-based therapy.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 科马尔·贾韦里 的研究动态
Follow Komal Jhaveri's research updates
留下邮箱，当我们发布与 Komal Jhaveri（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment